SCHEMBL4180960

SCHEMBL4180960

O=C1Nc2c(cccc2C(O)(C(F)(F)F)C(F)(F)F)C1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 0.71
LIG1 P18858 1/20 0.49
DAO P14920 2/20 0.49
NSD2 O96028 1/20 0.49
BCHE P06276 1/20 0.49
CASP3 P42574 1/20 0.43
CASP2 P42575 1/20 0.43
CASP7 P55210 1/20 0.43
CASP6 P55212 1/20 0.43
CASP8 Q14790 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.38
STK10 O94804 3/20 0.36
SLK Q9H2G2 3/20 0.36
GSK3B P49841 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594546 0.83 CES1 (1.00) CES1LIG1DAONSD2BCHE
Methane SCHEMBL28257010 0.81 CES1 (0.96) CES1LIG1DAONSD2BCHE
Ethane SCHEMBL28094093 0.80 CES1 (0.93) CES1LIG1DAONSD2BCHE
Toluene SCHEMBL28094090 0.77 CES1 (0.79) CES1LIG1DAONSD2BCHE
Butane SCHEMBL28094097 0.76 CES1 (0.84) CES1LIG1DAONSD2BCHE
SCHEMBL712833 0.76 CES1 (0.69) CES1LIG1DAONSD2BCHE
SCHEMBL2582219 0.70 MEN1 (0.52) KDM4EMEN1MAPTKMT2ALMNA
SCHEMBL31244367 0.70 CES1 (0.60) CES1LIG1DAONSD2BCHE
SCHEMBL5332282 0.70 CES1 (0.60) CES1LIG1DAONSD2BCHE
SCHEMBL29506270 0.70 CES1 (0.60) CES1LIG1DAONSD2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20090076077-A1 Methods and Compositions for Selectin Inhibition WYETH (US) 2009-03-19 US disclosed
US-20090076077-A1 Methods and Compositions for Selectin Inhibition WYETH (US) 2009-03-19 US disclosed
US-20090076077-A1 Methods and Compositions for Selectin Inhibition WYETH (US) 2009-03-19 US disclosed
US-7465799-B2 Methods and compositions for selectin inhibition WYETH (US) 2008-12-16 US disclosed
US-7465799-B2 Methods and compositions for selectin inhibition WYETH (US) 2008-12-16 US disclosed
US-7465799-B2 Methods and compositions for selectin inhibition WYETH (US) 2008-12-16 US disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed
EP-1682511-A2 METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION Wyeth (US) 2006-07-26 EP disclosed
WO-2005047257-A2 METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION WYETH (US) 2005-05-26 WO disclosed
US-20050101568-A1 Methods and compositions for selectin inhibition WYETH (US) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101568-A1 Methods and compositions for selectin inhibition SELP, SELE, SELL CES1 707/4885LIG1 3330/4885DAO 1610/4885
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE CES1 1128/4885LIG1 1558/4885DAO 1268/4885
US-20090076077-A1 Methods and Compositions for Selectin Inhibition SELP, SELE, SELL CES1 883/4885LIG1 3356/4885DAO 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.